The advancement of modern medicine, particularly in the intervention and treatment of cancer patients, has evolved to the gene level with the development of a targeted gene drug therapeutic regime. The outcome of the treatment has been proven to increase the chances of patient survival and cure. However, this new treatment requires preliminary laboratory molecular tests before and, in some cases, also after the treatment regimen is administered. Molecular laboratory tests require sufficient funding because the medical laboratory equipment used is relatively expensive to conduct tests on patients, and the existing funds are limited and insufficient. With these limited funds, many eligible patients who may benefit from this treatment are forced to opt for conventional treatment methods because molecular tests cannot be conducted. Therefore, financial assistance to cover the costs of equipment for these molecular tests is crucial. The establishment of a Health Waqf Fund specifically for this purpose will benefit cancer patients undergoing treatment at Sarawak General Hospital and UNIMAS Teaching Hospital. This facility also aims to serve the purposes of teaching, learning, and research for university medical students. Furthermore, this waqf fund will also expand its functions to cover molecular tests for other treatments and diagnostics. You are part of many patients’ new hope. Be part of our philanthropists.